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Abstract Application of biological agents targeting inﬂam-
matory cytokines such as tumor necrosis factor-α (TNF-α)
dramatically caused a paradigm shift in the treatment of
rheumatoid arthritis (RA). Inﬂiximab, a chimeric anti-TNF-
α  monoclonal antibody, has initially been introduced to
Japan in 2003 and shown to be dramatically effective in
alleviating arthritis refractory to conventional treatment.
However, serious adverse events such as bacterial pneumo-
nia, tuberculosis, and Pneumocystis jiroveci  pneumonia
were reported to be in relatively high incidence; i.e., 2%,
0.3%, and 0.4%, respectively, in a strict postmarketing sur-
veillance of an initial 4000 cases in Japan. Etancercept, a
recombinant chimeric protein consisting of p75 TNF-α re-
ceptor and human IgG, was subsequently introduced to
Japan in March of 2005. We therefore drew up treatment
guidelines for the use of etanercept to avoid potential
serous adverse events, since only approximately 150 cases
have been included in the clinical study of etanercept in
Japan. The guidelines were initially designed by the princi-
pal investigators (N.M, T.T., K.E.) of rheumatoid arthritis
study groups of the Ministry of Health, Labor and Welfare
(MHLW), Japan, and ﬁnally approved by the board of di-
rectors of the Japan College of Rheumatology. The MHLW
assigned a duty to the pharmaceutical companies to per-
form a complete postmarketing surveillance of an initial
3000 cases to explore any adverse events, and this was per-
formed according to the treatment guidelines shown in this
article.
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Introduction
In recent years, there has been a paradigm shift in the
treatment of rheumatoid arthritis (RA). It is mostly attrib-
uted to the introduction of biological agents targeting
inﬂammatory cytokines. Biological agents have approved
and marketed for the treatment of RA in Europe and the
United States include anti-tumor necrosis factor-α (TNF-α)
antibodies such as inﬂiximab (Remicade) adalimumab
(Humira), soluble TNF-α  receptor etanercept (Enbrel),
and interleukin (IL)-1 receptor antagonist anakinra
(Kineret). Among these, etanercept has drawn particular
attention as a highly effective and safe biological product in
the treatment of RA; it was approved in January 2005 in
Japan.
Efﬁcacy and adverse events of etanercept
Etanercept is a recombinant chimeric protein consisting of
two molecules of p75 and the Fc portion of human IgG1 and
is produced by introducing the fusion gene into Chinese
hamster ovary cells (molecular weight, approximately
150kDa; total amino acid residues, 934). As compared with
the natural-occurring soluble TNF-α receptor, etanercept
showed 50-fold greater binding to TNF-α, 100- to 1000-fold
greater biological activity, and 5- to 8-fold longer plasma
half-life; therefore, treatment of RA with etanercept has
been conducted.
1
In a phase III study in the United States involving 234
patients with active RA who were resistant to disease-
modifying antirheumatic drugs (DMARDs) including64
methotrexate (MTX), treatment with etanercept 25mg
showed signiﬁcantly greater efﬁcacy than etanercept 10mg
or placebo.
1 Analysis of adverse events revealed that the
incidence of injection-site reactions was signiﬁcantly higher
in the 25-mg dose group than other dose groups and that the
active treatment groups had a higher incidence of infec-
tions, i.e., upper respiratory tract infections, than the pla-
cebo group.
In a double-blind study of concomitant MTX, 89 patients
with active RA who had been treated with MTX for at least
6 months received either etanercept 25mg or placebo twice
a week subcutaneously in addition to MTX, resulting in
improvement in a 20% American College of Rheumatology
(ACR 20) response in 71% of patients receiving etanercept
and an ACR 50 improvement in 39% of patients receiving
etanercept. Moreover, there were no signiﬁcant differences
in incidence of adverse events such as infections between
the two groups.
2
On the basis of these results, etanercept was approved as
a treatment for RA by the Federal Drug Administration
(FDA) in the United States in November 1998. More than
6 years after its approval in the United States, the drug was
approved in January 2005 and has been marketed since the
end of March 2005 in Japan.
The most signiﬁcant beneﬁt of etanercept is to inhibit the
progression of joint destruction. Its efﬁcacy has been dem-
onstrated to be far superior to that of MTX, which is known
to have the potent effect of slowing the progression of joint
destruction.
3  The remarkable effectiveness of etanercept
has been shown particularly in the recently reported
TEMPO (Trial of Etanercept and Methotrexate with
Radiographic Patient Outcomes).
4 In this trial, 686 patients
with RA who were resistant to one or more DMARDs
other than MTX received one of the following three
treatments for 2 years: MTX alone, etanercept alone, or
etanercept plus MTX. The primary efﬁcacy endpoint was
the numeric index of the ACR response (ACR-N) area
under the curve (ACR-AUC) over the ﬁrst 24 weeks.
The primary endpoint did not differ signiﬁcantly between
the MTX monotherapy group and etanercept monotherapy
group; however, the etanercept plus MTX group had
signiﬁcantly higher ACR-AUC values than the two
monotherapy groups. The proportion of patients achieving
ACR 50, a clinically meaningful efﬁcacy, at 2 years was 71%
in the etanercept plus MTX group as compared with 42% in
the MTX monotherapy group and 54% in the etanercept
group, indicating greater efﬁcacy of the combination of
etanercept and MTX. Moreover, the change in total Sharp
Score at 1 year of treatment was −0.54 in the etanercept
plus MTX group as compared with +2.8 in the MTX
monotherapy group and +0.52 in the etanercept group,
suggesting the possibility that the combination may inhibit
the progression of joint destruction and even heal the
condition.
Frequently observed adverse events include injection-
site reactions, which are characterized by erythema with
pruritus, swelling, or pain at the injection sites. Most
reactions disappear with only topical treatments such as
antihistamines.
The most careful attention should be given to monitoring
for infections. Among the more than 1100 patients receiving
long-term treatment for at least 6 months, 50 experienced
serious infections such as pyelonephritis, bronchitis, septic
arthritis, and abscess formation, which were caused by
various types of organisms including bacteria, fungi, and
Pneumocystis jiroveci. Etanercept may mask clinical symp-
toms characteristic of infections, such as fever and chills,
and inhibit the production of acute inﬂammatory proteins,
thereby causing the problem of difﬁculty in detecting infec-
tions at an early stage.
In addition, occurrence of tuberculosis has recently
been of particular concern, although etanercept appears to
be rarely associated with tuberculosis as compared with
inﬂiximab.
5,6 However, caution should be exercised when
etanercept is used in Japan, where tuberculosis frequently
occurs,
7 because BCG vaccinations in Japan preclude the
use of the tuberculin skin test for screening at the start of
drug treatment, and there are not a few patients with drug-
resistant Mycobacterium tuberculosis.
8,9
Although the occurrence of malignancies was the most
serious among possible complications, the incidence in the
more than 1100 patients was not signiﬁcantly different from
the expected incidence in the general population. Also, pa-
tients with active RA have been shown to have a slightly
higher incidence of malignant lymphoma. In March 2003,
the FDA reported that the standardized incidence ratio
(SIR) for malignant lymphoma ranged from 2.3 to 3.5 in
patients receiving etanercept with no statistically signiﬁcant
difference.
10
Because etanercept is known to exacerbate congestive
heart failure, caution should be made when etanercept is
administered to patients with heart failure. Initially, clinical
trials were conducted with inﬂiximab or etanercept as a
therapeutic agent for congestive heart failure because TNF-
α was believed to be involved in the pathophysiology of
congestive heart failure. However, individual clinical trials
showed treatment failures and even worsening cases of con-
gestive heart failure, leading to termination of these trials.
11
In addition, rare cases of pancytopenia have been re-
ported. Although demyelinating diseases in the central ner-
vous system have also been reported, a causal relationship
to the treatment remains uncertain. In some patients with
multiple sclerosis, an increase in disease activity has been
found after the treatment.
12 A recent report showed that
etanercept treatment in early RA patients was well toler-
ated for up to 5 years.
13
In Japan, 147 patients who were refractory to con-
ventional DMARDs were enrolled in phase II clinical
study. Patients were randomly divided into three groups,
i.e., placebo group, 10mg twice-weekly group, and 25mg
twice-weekly group, and treated for 12 weeks. Conse-
quently, both the 10mg group and 25mg group yielded an
almost identical ACR20 response, signiﬁcantly better than
the placebo group (64.0%, 65.3% vs. 6.3%, respectively).
This trend was similar in both ACR50 and ACR70 re-
sponse. There was no signiﬁcant difference observed in se-
vere adverse effects between the etanercept and placebo
groups.65
Treatment guidelines for the use of etanercept
(Table 1)
14
For the safe use of etanercept in Japan, which produces
such high efﬁcacy and potential adverse events, the internal
medicine rheumatology study group of the Ministry of
Health, Labor and Welfare, Japan (led by N.M., T.T., and
K.E.) has developed the guidelines for treatment with
etanercept, which provide indications, contraindications,
and tuberculosis risk assessment, which was based on the
guidelines for the use of inﬂiximab for RA patients in
Japan
9 (Fig. 1). The guidelines were approved by the board
of directors of Japan College of Rheumatology.
Etanercept is indicated in patients with active RA at
or above a certain level. Speciﬁcally, etanercept may be
used in patients who have inadequately been controlled
despite treatment of at least 3 months with the usual
doses of one of the DMARDs (methotrexate, bucillamine,
or sulfasalazine), which are rated as “recommendation A
level” in the Diagnostic Manual and Evidence-based Treat-
ment Guidelines
15  developed by the study group of the
Ministry of Health, Labor and Welfare. Leﬂunomide, an-
other DMARD rated as recommendation A, is not included
in the present guidelines because of the adverse event of
serious interstitial pneumonia observed in Japan.
16  Inad-
equate response to previous treatment is deﬁned by the
presence of at least six tender joints and swollen joints and
either C-reactive protein levels of at least 2.0mg/dl or eryth-
rocyte sedimentation rate (ESR) of at least 28mm/h.
To avoid potential opportunistic infections, patients
should have a peripheral leukocyte count of 4000/mm
3 or
more, peripheral lymphocyte count of 1000/mm
3 or more,
and a negative test for blood β-d-glucan. These criteria are
based on the ﬁndings that cellular immunity plays an impor-
tant role in opportunistic infections caused by Mycobacte-
rium tuberculosis  or fungi such as Pneumocystis jiroveci,
and that these infections are likely to occur in patients with
decreased peripheral lymphocyte counts.
17 A test for blood
β-d-glucan has been included because β-d-glucan, a compo-
nent of fungi, may be diagnostic of fungal infections, espe-
cially infections with Pneumocystis jiroveci.
The recommended dosage and administration of
etanercept in Japan is 10–25mg given once daily and twice
weekly as a subcutaneous injection. In this aspect, once-
weekly administration of 50mg etanercept in patients
with active RA patients has been approved in the United
States, and this dosing regimen was shown to be equivalent
to 25mg etanercept twice weekly in terms of safety, efﬁcacy,
and pharmacokinetics.
18 Patients will switch to self-injection
Table 1. Treatment guidelines for the use of etanercept
A. Inclusion criteria
Patients with active rheumatoid arthritis still presenting the following despite the use of one or more MHLW recommendation-level-A-
DMARDs
a (methotrexate, bucillamine, or sulfasalazine) at a normal dose for more than 3 months:
(1) Tender joints ≥6
(2) Swollen joints ≥6
(3) ESR ≥28mm/h or CRP ≥2.0mg/dl
Also, the patients must meet the following as having low risk for opportunistic infections:
(1) WBC ≥4000/mm
3
(2) Peripheral blood lymphocytes ≥1000/mm
3
(3) Serum β-d-glucan: negative
B. Usage
The dose of etanercept is 10–25mg administered twice weekly as a subcutaneous injection. A patient can self-inject etanercept only after the
ability to self-inject is carefully assessed and appropriate training is provided by a health professional.
C. Contraindication
1. Ongoing infection
2. Past history of serious infections in the last 6 months
3. Abnormal shadows on chest radiographs suggestive of old pulmonary tuberculosis (TB) or tuberculosis pleuritis
4. History of extra pulmonary TB or Pneumocystis carinii pneumonia
5. Congestive heart failure
6. Malignancy or demyelinating disease
D. Caution
1. From the point of view of screening for infection (especially TB and opportunistic infections) as well as prevention of side effects,
etanercept is recommended for clinical use at medical institutes where:
(1) Chest X-rays can be obtained on the same day, and the X-ray can be interpreted by a pulmonologist, TB specialist, or radiologist
(2) Opportunistic infections can be treated
2. Comprehensive TB screening should be conducted including an in-depth patient history, chest radiographs (chest CT whenever possible)
and a PPD skin test. In patients with suspected TB, based on medical history, abnormal shadows on chest radiographs suggestive of old
pulmonary TB, or with a PPD skin test positive (as evidenced by redness of at least 20mm in diameter or the presence of induration),
the treatment with etanercept may be considered in addition to anti-tuberculosis drugs only if the potential beneﬁts outweigh the
potential risks.
MHLW, Ministry of Health, Labor and Welfare; DMARD, disease-modifying antirheumatic drug; ESR, erythrocyte sedimentation rate; CRP,
C-reactive protein; WBC, white blood cells; TB, tuberculosis; CT, computed tomography; PPD, puriﬁed protein derivative
aCited in the Diagnostic Manual and Evidence-based Treatment Guidelines66
after they are assessed as capable of conducting self-
injections and receive adequate instructions. Etanercept
may be used as monotherapy as the drug was administered
so in clinical trials in Japan. In Europe and the United
States, however, etanercept in combination with MTX
has been demonstrated to provide greater efﬁcacy in
TEMPO.
4 Thus, the combination of etanercept with MTX
should be considered in patients with highly active disease
in Japan.
Etanercept is contraindicated in patients with active in-
fections or a history of serious infections within the previous
6 months. In addition, careful assessment of the risk of
tuberculosis should be made. Speciﬁcally, the following
three examinations should be performed before treatment
initiation: interview with respect to family and past history
of tuberculosis, chest radiography, and puriﬁed protein de-
rivative (PPD) skin test (Fig. 1). Chest radiographs should
preferably be interpreted by a specialist in pulmonology,
tuberculosis, or radiology. When abnormalities are sus-
pected on chest radiography, computed tomography of the
chest should be performed. Etanercept is contraindicated in
patients with abnormalities in chest radiographs such as
linear opacities, calciﬁcation ≥5mm, and pleural thickening
suggesting old pulmonary tuberculosis, and individuals
infected with pulmonary or extrapulmonary tuberculosis.
However, treatment with etanercept may be considered
with antituberculous agents only if the potential beneﬁts
outweigh the potential risks. In patients with a positive PPD
skin test (as evidenced by erythema of at least 20mm in
diameter or the presence of induration) or opacities sug-
gesting old pulmonary tuberculosis on chest radiographs,
treatment with isoniazid 0.3g/day should be initiated at
least 1 month prior to administration of etanercept and
continued for the subsequent 9 months. However, no
deﬁnite guidelines are available that address how to deal
with isoniazid-induced hepatic impairment and isoniazid-
resistant Mycobacterium tuberculosis, as well as how long
isoniazid treatment should be given. Etanercept is also
contraindicated in patients with previous Pneumocystis
jiroveci pneumonia, congestive heart failure, malignancies,
or demyelinating disease.
To sum up, in this article we focused on the guidelines for
the use of etanercept that have been introduced in Japan
since spring 2005. In Japan, because only about 100 patients
received etanercept in clinical trials, it remains uncertain
whether etanercept yields clinical beneﬁt and adverse
events with a similar frequency as observed in Europe and
the United States. Nonetheless, we will conduct an all-cases
postmarketing surveillance using the above-mentioned
treatment guidelines, review the results, and revise the
guidelines as needed.
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